Immutep Limited (NASDAQ:IMMP) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 132,600 shares, a growth of 140.2% from the December 15th total of 55,200 shares. Based on an average daily trading volume, of 338,800 shares, the short-interest ratio is presently 0.4 days.
Several large investors have recently added to or reduced their stakes in IMMP. Saturna Capital CORP increased its position in shares of Immutep by 3.4% during the 3rd quarter. Saturna Capital CORP now owns 92,500 shares of the biotechnology company's stock valued at $358,000 after purchasing an additional 3,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Immutep by 54.3% in the 3rd quarter. Geode Capital Management LLC now owns 18,722 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 6,591 shares in the last quarter. Jump Financial LLC raised its position in shares of Immutep by 40.1% in the 3rd quarter. Jump Financial LLC now owns 33,761 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 9,661 shares in the last quarter. Lindbrook Capital LLC bought a new position in Immutep during the 3rd quarter valued at approximately $39,000. Finally, Beirne Wealth Consulting Services LLC bought a new position in Immutep during the 3rd quarter valued at approximately $39,000. Institutional investors own 9.34% of the company's stock.
Several research firms recently weighed in on IMMP. Zacks Investment Research raised Immutep from a "sell" rating to a "hold" rating in a research note on Wednesday, November 3rd. Jefferies Financial Group assumed coverage on Immutep in a research note on Thursday, December 2nd. They issued a "buy" rating on the stock.
Shares of NASDAQ:IMMP opened at $3.24 on Friday. The business's 50 day moving average is $3.54 and its 200 day moving average is $3.77. The company has a quick ratio of 12.81, a current ratio of 12.81 and a debt-to-equity ratio of 0.03. Immutep has a 12-month low of $2.20 and a 12-month high of $5.44.
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Featured Article: Compound Interest
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here